@article{10902/29931,
year = {2023},
url = {https://hdl.handle.net/10902/29931},
abstract = {Interstitial lung disease (ILD) constitutes the most critical comorbidity in autoimmune diseases (ADs) and its early diagnosis remains a challenge for clinicians. Accordingly, we evaluated whether E-selectin, ICAM-1, and ET-1, key molecules in endothelial damage, could be useful biomarkers for the detection of AD-ILD+ . We recruited patients with rheumatoid arthritis (RA)-ILD+ (n = 21) and systemic sclerosis (SSc)-ILD+ (n = 21). We included comparison groups of patients: RA-ILD− (n = 25), SSc-ILD− (n = 20), and idiopathic pulmonary fibrosis (IPF) (n = 21). Serum levels of these proteins were determined by ELISA. E-selectin, ICAM-1, and ET-1 serum levels were increased in RA-ILD+ and IPF patients in comparison to RA-ILD− patients. Additionally, SSc-ILD+ and IPF patients exhibited higher ICAM-1 levels than those with SSc-ILD−. The ability of E-selectin, ICAM-1, and ET-1 to discriminate RA-ILD+ from RA-ILD− patients, and ICAM-1 to distinguish SSc-ILD+ from SSc-ILD− patients was confirmed using ROC curve analysis. Furthermore, elevated levels of ET-1 and E-selectin correlated with lung function decline in RA-ILD+ and SSc-ILD+ patients, respectively. In conclusion, our findings support the relevant role of E-selectin, ICAM-1, and ET-1 in RA-ILD+ patients as well as of ICAM-1 in SSc-ILD+ patients, constituting potential screening blood biomarkers of ILD in AD. Moreover, this study suggests ET-1 and E-selectin as possible indicators of worsening lung function in RA-ILD+ and SSc-ILD+ patients, respectively},
organization = {Funding: MSM-G is financed by funds of PI21/00042 from ISCIII, co-funded by the ESF; RL-M is a recipient of a Miguel Servet type II Program fellowship from ISCIII, co-funded by the ESF, ‘Investing in your future’ (CPII21/00004)},
publisher = {MDPI},
publisher = {International journal of molecular sciences, 2023, 24(15), 12518},
title = {E-Selectin, ICAM-1, and ET-1 biomarkers address the concern of the challenging diagnosis of interstitial lung disease in patients with autoimmune diseases},
author = {Remuzgo-Martínez, Sara and Genre, Fernanda and Atienza Mateo, Belén  and Mora-Cuesta, Víctor M. and Iturbe-Fernández, David and Lera-Gómez, Leticia and Sebastián Mora-Gil, María and Portilla, Virginia and Corrales, Alfonso and Blanco Alonso, Ricardo and Cifrián Martínez, José Manuel and González-Gay Mantecón, Miguel Ángel},
}